Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.

Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang CJ, Yarchoan R, Cheever MA; Cancer Immunotherapy Trials Network (CITN)-12 Study Team.

JAMA Oncol. 2019 Jun 2. doi: 10.1001/jamaoncol.2019.2244. [Epub ahead of print]

PMID:
31154457
2.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
3.

Tuberculosis following PD-1 blockade for cancer immunotherapy.

Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, Ashkin D, Cheng JH, Lundgren LM, Raabe VN, Kraft CS, Nieva JJ, Cheever MA, Nghiem PT, Sharon E.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaat2702. doi: 10.1126/scitranslmed.aat2702.

PMID:
30651320
4.

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.

Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren N, Shinohara MM, Kluger HM, Bhatia S, Lundgren L, Cheever MA, Topalian SL, Nghiem P.

J Immunother Cancer. 2018 Nov 27;6(1):131. doi: 10.1186/s40425-018-0450-7.

5.

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.

Giraldo NA, Nguyen P, Engle EL, Kaunitz GJ, Cottrell TR, Berry S, Green B, Soni A, Cuda JD, Stein JE, Sunshine JC, Succaria F, Xu H, Ogurtsova A, Danilova L, Church CD, Miller NJ, Fling S, Lundgren L, Ramchurren N, Yearley JH, Lipson EJ, Cheever M, Anders RA, Nghiem PT, Topalian SL, Taube JM.

J Immunother Cancer. 2018 Oct 1;6(1):99. doi: 10.1186/s40425-018-0404-0.

6.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25.

PMID:
30045932
7.

Gene expression markers of Tumor Infiltrating Leukocytes.

Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP.

J Immunother Cancer. 2017 Feb 21;5:18. doi: 10.1186/s40425-017-0215-8. eCollection 2017.

8.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA.

N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19.

9.

Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.

Hoffenberg S, Powell R, Carpov A, Wagner D, Wilson A, Kosakovsky Pond S, Lindsay R, Arendt H, Destefano J, Phogat S, Poignard P, Fling SP, Simek M, Labranche C, Montefiori D, Wrin T, Phung P, Burton D, Koff W, King CR, Parks CL, Caulfield MJ.

J Virol. 2013 May;87(10):5372-83. doi: 10.1128/JVI.02827-12. Epub 2013 Mar 6.

10.

A novel role for an endothelial adrenergic receptor system in mediating catecholestradiol-induced proliferation of uterine artery endothelial cells.

Jobe SO, Fling SN, Ramadoss J, Magness RR.

Hypertension. 2011 Nov;58(5):874-81. doi: 10.1161/HYPERTENSIONAHA.111.178046. Epub 2011 Sep 26.

11.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

12.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.

13.

The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics.

Bazin HG, Murray TJ, Bowen WS, Mozaffarian A, Fling SP, Bess LS, Livesay MT, Arnold JS, Johnson CL, Ryter KT, Cluff CW, Evans JT, Johnson DA.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4. doi: 10.1016/j.bmcl.2008.09.060. Epub 2008 Sep 19.

PMID:
18835160
14.

A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.

Fort MM, Mozaffarian A, Stöver AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P, Jeffery E, Fling SP, Hershberg RM.

J Immunol. 2005 May 15;174(10):6416-23.

15.

Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis.

Louie KA, Weiner LP, Du J, Kochounian HH, Fling SP, Wei W, McMillan M.

Gene Ther. 2005 Jul;12(14):1145-53.

PMID:
15772685
16.

Human CD8+ T cells recognize the 60-kDa cysteine-rich outer membrane protein from Chlamydia trachomatis.

Gervassi AL, Grabstein KH, Probst P, Hess B, Alderson MR, Fling SP.

J Immunol. 2004 Dec 1;173(11):6905-13.

17.

An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response.

Starnbach MN, Loomis WP, Ovendale P, Regan D, Hess B, Alderson MR, Fling SP.

J Immunol. 2003 Nov 1;171(9):4742-9.

19.

Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis.

Coler RN, Campos-Neto A, Ovendale P, Day FH, Fling SP, Zhu L, Serbina N, Flynn JL, Reed SG, Alderson MR.

J Immunol. 2001 May 15;166(10):6227-35.

20.

CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis.

Fling SP, Sutherland RA, Steele LN, Hess B, D'Orazio SE, Maisonneuve J, Lampe MF, Probst P, Starnbach MN.

Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1160-5.

21.

Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity.

Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, Grabstein KH, Alderson MR.

J Immunol. 2001 Jan 1;166(1):439-46.

22.
23.
24.
25.
26.
27.

Unresponsiveness to self-peptides of S-antigen in EAU: an overview of recent results.

Gregerson DS, Fling SP, Donoso LA, Gold DP.

Curr Eye Res. 1992;11 Suppl:67-74. Review.

PMID:
1385044
28.

In vitro unresponsiveness to autologous sequences of the immunopathogenic autoantigen, S-antigen.

Fling SP, Donoso LA, Gregerson DS.

J Immunol. 1991 Jul 15;147(2):483-9.

PMID:
1712808
29.

Conserved T cell receptor V gene usage by uveitogenic T cells.

Gregerson DS, Fling SP, Merryman CF, Zhang XM, Li XB, Heber-Katz E.

Clin Immunol Immunopathol. 1991 Jan;58(1):154-61.

PMID:
1983968
30.

The use of synthetic peptides in the study of experimental autoimmune uveitis.

Donoso LA, Gregerson DS, Fling SP, Merryman CF, Sery TW.

Curr Eye Res. 1990;9 Suppl:155-61. Review.

PMID:
1696532
31.

A new perspective of S-antigen from immunochemical analysis.

Gregerson DS, Fling SP, Obritsch WF, Merryman CF, Donoso LA.

Curr Eye Res. 1990;9 Suppl:145-53.

PMID:
1696531
32.

Multiple, spatially distinct T cell epitopes within a pathogenic 123 residue cyanogen bromide peptide of bovine retinal s-antigen.

Fling SP, Gregerson DS, Obritsch WF, Boyce-Jacino M, Merryman CF, Donoso LA.

Curr Eye Res. 1990;9 Suppl:111-7.

PMID:
1696530
33.

Identification of T cell recognition sites in S-antigen: dissociation of proliferative and pathogenic sites.

Gregerson DS, Fling SP, Obritsch WF, Merryman CF, Donoso LA.

Cell Immunol. 1989 Oct 15;123(2):427-40.

PMID:
2790968
34.
35.
36.
37.

Characterization of immunologically active cyanogen bromide peptide fragments of bovine and human retinal S-antigen.

Gregerson DS, Fling SP, Wohlhueter RM.

Exp Eye Res. 1986 Nov;43(5):803-18.

PMID:
2433138
38.
39.
40.

Maternal holding preferences: a consequence of newborn head-turning response.

Ginsburg HJ, Fling S, Hope ML, Musgrove D, Andrews C.

Child Dev. 1979 Mar;50(1):280-1.

PMID:
446214
41.

Imaginary companions in young children: relationships with intelligence, creativity and waiting ability.

Manosevitz M, Fling S, Prentice NM.

J Child Psychol Psychiatry. 1977 Jan;18(1):73-8. No abstract available.

PMID:
838788

Supplemental Content

Support Center